3-Hydroxy-2-phenylquinoline-4-carboxylic acid, 95.0%, 1g

(2S,3R)-Methyl 2-acetamido-3-hydroxybutanoate, 95.0%, 1g

5,6-Diiodobenzo[d][1,3]dioxole, 98%, 100mg

Fmoc-(S)-3-Amino-3-(4-trifluoromethylphenyl)-propionic acid, 97%, 10g

iScope IS.1153-PLi/DFi Triocular with Plan IOS objectives and Rackless cross stage (dark field contrast application)

tert-Butyl (1S,4R)-6-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylate, 98%, 250mg

3-Amino-3-(3-methoxyphenyl)propanenitrile hydrochloride, 95.0%, 250mg

(3-Isopropyl-1,2,4-oxadiazol-5-yl)methanol, 95.0%, 250mg

TERT-BUTYL 1,1-DIOXO-1,2,5-THIADIAZOLIDINE-2-CARBOXYLATE, 95.0%, 250mg

2,5-Dichlorobenzhydrazide, 98.0%, 1g

2-Chloro-1-(4-phenylpiperazin-1-yl)ethanone, 95.0%, 2g

[S(R)]-N-[(1S)-1-[5-(Diphenylphosphino)-9,9-dimethyl-9H-xanthen-4-yl]-2,2-dimethylpropyl]-2-methyl-2-propanesulfinamide, 95%, 100mg

6-(Methoxymethyl)picolinic acid, 98%, 1g